Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Inventory (2016 - 2025)

Historic Inventory for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to $3.4 million.

  • Sanara MedTech's Inventory rose 1255.2% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 1255.2%. This contributed to the annual value of $2.8 million for FY2024, which is 4164.25% down from last year.
  • Latest data reveals that Sanara MedTech reported Inventory of $3.4 million as of Q3 2025, which was up 1255.2% from $3.5 million recorded in Q2 2025.
  • Sanara MedTech's 5-year Inventory high stood at $5.0 million for Q3 2023, and its period low was $1.2 million during Q1 2021.
  • For the 5-year period, Sanara MedTech's Inventory averaged around $3.1 million, with its median value being $3.4 million (2025).
  • Its Inventory has fluctuated over the past 5 years, first soared by 14055.46% in 2022, then tumbled by 4164.25% in 2024.
  • Quarter analysis of 5 years shows Sanara MedTech's Inventory stood at $2.0 million in 2021, then soared by 73.27% to $3.5 million in 2022, then surged by 32.93% to $4.7 million in 2023, then tumbled by 41.64% to $2.8 million in 2024, then increased by 22.99% to $3.4 million in 2025.
  • Its Inventory stands at $3.4 million for Q3 2025, versus $3.5 million for Q2 2025 and $3.2 million for Q1 2025.